Search | Clinical Trials Finder

Conditions: Hypernatremia
Interventions: Intravenous Dextrose 5% solution; Drug
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Dry Eye
Interventions: Secukinumab 10 mg/kg, Canakinumab 10 mg/kg, Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: HRD Cancer, SCLC, Advanced Solid Tumors
Interventions: Berzosertib, Sacituzumab Govitecan; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Blood Pressure, Hypertension
Interventions: Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Schizophrenia
Interventions: NRX-1074, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Solid Tumours
Interventions: SB-715992, carboplatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bacterial Infections
Interventions: Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole; Drug
Lead sponsor: Debiopharm International SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Osteogenesis Imperfecta
Interventions: Setrusumab, Placebo; Biological · Other
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 5 Years to 25 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 23
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 20 more

Conditions: Angina, Unstable, Cardiovascular Diseases, Heart Diseases, Coronary Disease, Myocardial Infarction, Heart Failure, Congestive
Interventions: GIK, Placebo; Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 30 Years and older
Enrollment: 911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 13
States / cities: Anchorage, Alaska • New Haven, Connecticut • Macon, Georgia + 10 more

Conditions: Hypertension
Interventions: DEFINITY® infusion, Human Recombinant Regular Insulin infusion, Dextrose infusion, Flow mediated vasodilation, Endothelial cell collection, Microvascular perfusion assessment using Definity, Microneurography; Drug · Procedure
Lead sponsor: Wanpen Vongpatanasin; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Colon Cancer Liver Metastasis
Interventions: Lyso-Thermosensitive Liposomal Doxorubicin, 5% Dextrose Solution, ThermoDox; Drug · Other
Lead sponsor: Imunon; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • The Bronx, New York • Cleveland, Ohio + 1 more

Conditions: Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer, Gastrointestinal Cancer, Appendiceal Cancer, Atypical Mesothelial Proliferation, Colorectal Cancer
Interventions: Sodium Thiosulfate, 5-Fluorouracil, Oxaliplatin, Doxorubicin, Hyperthermic Intraperitonial Chemotherapy, Cisplatin, Mitomycin C; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Heart Failure, Cardiorenal Disease, Renal Disfunction
Interventions: ANX-042, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Fungal Infection
Interventions: Placebo, Rezafungin; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Tolerability, Healthy, Elderly
Interventions: AZD9742, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 65 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Docetaxel, Prednisone, Placebo, Dexamethasone; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 24 more

Conditions: Induced Labor
Interventions: 5% Dextrose (D5) in Normal Saline (NS), Lactate Ringer; Drug
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years and older · Female only
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Severe Acute Respiratory Syndrome
Interventions: Otilimab, Placebo 1, Placebo 2, Standard of care; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 21
States / cities: Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more

Conditions: Gastroenteritis, Dehydration
Interventions: 5% dextrose in normal saline; Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 6 Years
Enrollment: 188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Length of Labor, Second Stage of Labor, Intravenous Hydration of Labor
Interventions: Dextrose, Normal Saline; Other
Lead sponsor: MemorialCare Health System; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Photosensitive Epilepsy
Interventions: Valproic Acid, Placebo; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Chesterfield, Missouri • Nashville, Tennessee

Conditions: West Nile Virus
Interventions: Omr-lgG-am, Polygam® S/D, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 66
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
Interventions: Pembrolizumab, Placebo for pembrolizumab, Carboplatin, Paclitaxel, Olaparib, Placebo for olaparib, Bevacizumab, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,367 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 43
States / cities: Birmingham, Alabama • Tucson, Arizona • Burbank, California + 37 more

Conditions: Chronic Subdural Hematoma
Interventions: Dextrose 5% W/ Sodium Chloride 0.225%; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Search by objective public record fields.

Rapid Rehydration for Severe Hypernatremia

The Effects of a Single Intravenous Administration of Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Patients

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Reversing Glucose and Lipid-mediated Vascular Dysfunction

NRX-1074 in Early Course Schizophrenia

Ispinesib In Combination With Carboplatin In Patients With Solid Tumors

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Setrusumab vs Placebo for Osteogenesis Imperfecta

IMMEDIATE Trial - Out of Hospital Administration of Glucose, Insulin and Potassium.

Neural Mechanism of Aldosterone-induced Insulin Resistance

Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)

Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies

Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome

Safety and Pharmacokinetics of Rezafungin

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)

Lactated Ringer's and Dextrose 5% vs Only Lactated Ringer's in Labor

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

Study Investigating the Use of Intravenous Fluids With Dextrose for Dehydrated Children

Effects of Rate and/or Presence of Dextrose on the Labor Course of Nulliparas

Effect of Valproic Acid Concentration on Photic Response

IVIG - West Nile Encephalitis: Safety and Efficacy

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)

Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence